5bnr: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:


==E. coli Fabh with small molecule inhibitor 2==
==E. coli Fabh with small molecule inhibitor 2==
<StructureSection load='5bnr' size='340' side='right' caption='[[5bnr]], [[Resolution|resolution]] 1.89&Aring;' scene=''>
<StructureSection load='5bnr' size='340' side='right'caption='[[5bnr]], [[Resolution|resolution]] 1.89&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[5bnr]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5BNR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5BNR FirstGlance]. <br>
<table><tr><td colspan='2'>[[5bnr]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Ecoli Ecoli]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5BNR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5BNR FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4VL:1-{5-[2-FLUORO-5-(HYDROXYMETHYL)PHENYL]PYRIDIN-2-YL}PIPERIDINE-4-CARBOXYLIC+ACID'>4VL</scene></td></tr>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4VL:1-{5-[2-FLUORO-5-(HYDROXYMETHYL)PHENYL]PYRIDIN-2-YL}PIPERIDINE-4-CARBOXYLIC+ACID'>4VL</scene></td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5bnm|5bnm]], [[5bns|5bns]], [[5bqs|5bqs]]</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5bnm|5bnm]], [[5bns|5bns]], [[5bqs|5bqs]]</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">fabH, b1091, JW1077 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=83333 ECOLI])</td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Beta-ketoacyl-[acyl-carrier-protein]_synthase_III Beta-ketoacyl-[acyl-carrier-protein] synthase III], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.180 2.3.1.180] </span></td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Beta-ketoacyl-[acyl-carrier-protein]_synthase_III Beta-ketoacyl-[acyl-carrier-protein] synthase III], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.180 2.3.1.180] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5bnr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5bnr OCA], [http://pdbe.org/5bnr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5bnr RCSB], [http://www.ebi.ac.uk/pdbsum/5bnr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5bnr ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5bnr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5bnr OCA], [http://pdbe.org/5bnr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5bnr RCSB], [http://www.ebi.ac.uk/pdbsum/5bnr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5bnr ProSAT]</span></td></tr>
Line 20: Line 21:
</div>
</div>
<div class="pdbe-citations 5bnr" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 5bnr" style="background-color:#fffaf0;"></div>
==See Also==
*[[Acyl carrier protein synthase 3D structures|Acyl carrier protein synthase 3D structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Ecoli]]
[[Category: Large Structures]]
[[Category: Kazmirski, S L]]
[[Category: Kazmirski, S L]]
[[Category: McKinney, D C]]
[[Category: McKinney, D C]]

Revision as of 11:51, 11 March 2020

E. coli Fabh with small molecule inhibitor 2E. coli Fabh with small molecule inhibitor 2

Structural highlights

5bnr is a 1 chain structure with sequence from Ecoli. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:
Gene:fabH, b1091, JW1077 (ECOLI)
Activity:[acyl-carrier-protein_synthase_III Beta-ketoacyl-[acyl-carrier-protein] synthase III], with EC number 2.3.1.180
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

[FABH_ECOLI] Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate specificity for acetyl-CoA. Its substrate specificity determines the biosynthesis of straight-chain of fatty acids instead of branched-chain.[HAMAP-Rule:MF_01815]

Publication Abstract from PubMed

Fatty acid biosynthesis is essential to bacterial growth in Gram-negative pathogens. Several small molecules identified through a combination of high-throughput and fragment screening were cocrystallized with FabH (beta-ketoacyl-acyl carrier protein synthase III) from Escherichia coli and Streptococcus pneumoniae. Structure-based drug design was used to merge several scaffolds to provide a new class of inhibitors. After optimization for Gram-negative enzyme inhibitory potency, several compounds demonstrated antimicrobial activity against an efflux-negative strain of Haemophilus influenzae. Mutants resistant to these compounds had mutations in the FabH gene near the catalytic triad, validating FabH as a target for antimicrobial drug discovery.

Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.,McKinney DC, Eyermann CJ, Gu RF, Hu J, Kazmirski SL, Lahiri SD, McKenzie AR, Shapiro AB, Breault G ACS Infect Dis. 2016 Jul 8;2(7):456-64. doi: 10.1021/acsinfecdis.6b00053. Epub, 2016 May 9. PMID:27626097[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. McKinney DC, Eyermann CJ, Gu RF, Hu J, Kazmirski SL, Lahiri SD, McKenzie AR, Shapiro AB, Breault G. Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping. ACS Infect Dis. 2016 Jul 8;2(7):456-64. doi: 10.1021/acsinfecdis.6b00053. Epub, 2016 May 9. PMID:27626097 doi:http://dx.doi.org/10.1021/acsinfecdis.6b00053

5bnr, resolution 1.89Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA